Abstract
Background: Recent clinical trial studies have reported that L-carnitine supplementation
can reduce the mortality rate in patients with sepsis, but there are no definitive results in this context.
The current systematic review and meta-analysis aimed to evaluate the effect of L-carnitine supplementation
on 28-day and one-year mortality in septic patients.
Methods: A systematic search conducted on Pubmed, Scopus and Cochrane Library databases up to
June 2019 without any language restriction. The publications were reviewed based on the Cochrane
handbook and preferred reporting items for systematic reviews and meta-analyses (PRISMA). To
compare the effects of L-carnitine with placebo, Risk Ratio (RR) with 95% confidence intervals (CI)
were pooled according to the random effects model.
Results: Across five enrolled clinical trials, we found that L-carnitine supplementation reduce one-year
mortality in septic patients with SOFA> 12 (RR: 0.68; 95% CI: 0.49 to 0.96; P= 0.03) but had no significant
effect on reducing 28-day mortality ((RR: 0.93; 95% CI: 0.68 to 1.28; P= 0.65) compared to
placebo. Finally, we observed that based on current trials, L-carnitine supplementation may not have
clinically a significant effect on mortality rate.
Conclusion: L-carnitine patients with higher SOFA score can reduce the mortality rate. However, the
number of trials, study duration and using a dosage of L-carnitine are limited in this context and further
large prospective trials are required to clarify the effect of L-carnitine on mortality rate in septic patients.
Keywords:
L-carnitine, sepsis, mortality, SOFA, clinical trial, meta-analysis.
Graphical Abstract
[3]
Rhodes, A.; Evans, L.E.; Alhazzani, W.; Levy, M.M.; Antonelli, M.; Ferrer, R.; Kumar, A.; Sevransky, J.E.; Sprung, C.L.; Nunnally, M.E.; Rochwerg, B.; Rubenfeld, G.D.; Angus, D.C.; Annane, D.; Beale, R.J.; Bellinghan, G.J.; Bernard, G.R.; Chiche, J.D.; Coopersmith, C.; De Backer, D.P.; French, C.J.; Fujishima, S.; Gerlach, H.; Hidalgo, J.L.; Hollenberg, S.M.; Jones, A.E.; Karnad, D.R.; Kleinpell, R.M.; Koh, Y.; Lisboa, T.C.; Machado, F.R.; Marini, J.J.; Marshall, J.C.; Mazuski, J.E.; McIntyre, L.A.; McLean, A.S.; Mehta, S.; Moreno, R.P.; Myburgh, J.; Navalesi, P.; Nishida, O.; Osborn, T.M.; Perner, A.; Plunkett, C.M.; Ranieri, M.; Schorr, C.A.; Seckel, M.A.; Seymour, C.W.; Shieh, L.; Shukri, K.A.; Simpson, S.Q.; Singer, M.; Thompson, B.T.; Townsend, S.R.; Van der Poll, T.; Vincent, J.L.; Wiersinga, W.J.; Zimmerman, J.L.; Dellinger, R.P. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016.
Intensive Care Med., 2017,
43(3), 304-377.
[
http://dx.doi.org/10.1007/s00134-017-4683-6] [PMID:
28101605]
[17]
Higgins, J.P.; Green, S. Cochrane handbook for systematic reviews of interventions; John Wiley & Sons, 2011.
[19]
Jones, AE; Puskarich, MA; Shapiro, NI; Guirgis, FW; Runyon, M; Adams, JY .Effect of levocarnitine vs placebo as an adjunctive treatment for septic shock: the rapid administration of carnitine in sepsis (RACE) randomized clinical trial. JAMA Network Open, 2018, 1(8), e186076-e..
[23]
Sedighiyan, M.; Abdolahi, M.; Taheri, E.; Qorbani, M.; Omidian, P.; Hosseini, S. The French maritime pine bark extract reduce metabolic syndrome risk and improve body composition in obesity: a new clinical approach. Acta Med. Iran., 2018, 56(3), 196-203.
[25]
Sedighiyan, M.; Abdolahi, M.; Honarvar, N.M.; Hosseini, B.; Djafarian, K. Curcumin a novel agent targeting inflammatory pathways in obesity. J. Nutr. Sci. & Diet., 2016, 2(4)
[29]
Kompare, M.; Rizzo, W.B., Eds.; Mitochondrial fatty-acid oxidation disorders. Seminars in pediatric neurology; Elsevier, 2008.
[30]
Longo, N.; Amat di San Filippo, C.; Pasquali, M., Eds.; Disorders of carnitine transport and the carnitine cycle. American Journal of Medical Genetics Part C: Seminars in Medical Genetics; Wiley Online Library, 2006.